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Abstract
Acute tryptophan depletion (ATD) is a method of lowering brain serotonin (5-HT). Administration of large neutral amino
acids (LNAA) limits the transport of endogenous tryptophan (TRP) across the blood brain barrier by competition with other
LNAAs and subsequently decreases serotonergic neurotransmission. A recent discussion on the specificity and efficacy of
the ATD paradigm for inhibition of central nervous 5-HT has arisen. Moreover, side effects such as vomiting and nausea after
intake of amino acids (AA) still limit its use. ATD Moja-De is a revised mixture of AAs which is less nauseating than
conventional protocols. It has been used in preliminary clinical studies but its effects on central 5-HT mechanisms and other
neurotransmitter systems have not been validated in an animal model. We tested ATD Moja-De (TRP2) in two strains of
mice: C57BL/6J, and BALB/cJ, which are reported to have impaired 5-HT synthesis and a more anxious phenotype relative to
other strains of mice. ATD Moja-De lowered brain TRP, significantly decreased 5-HT synthesis as indexed by 5-HTP levels
after decarboxlyase inhibition, and lowered 5-HT and 5-HIAA in both strains of mice, however more so in C57BL/6J than in
BALB/cJ. Dopamine and its metabolites as well as norepinephrine were not affected. A balanced (TRP+) control mixture did
not raise 5-HT or 5-HIAA. The present findings suggest that ATD Moja-De effectively and specifically suppresses central
serotonergic function. These results also demonstrate a strain- specific effect of ATD Moja-De on anxiety-like behavior.
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Introduction
The neurotransmitter serotonin (5-HT) plays a key role in many
physiological processes, including cognition and mood, which are
typically affected in clinical depression and anxiety disorder. A
well-established method to study the effects of 5-HT in the human
brain is to lower the central nervous 5-HT synthesis rate by
diminishing the availability of tryptophan (TRP), the amino acid
precursor of 5-HT. This technique is called acute tryptophan
depletion (ATD). The rate controlling step in central nervous 5-
HT synthesis is the conversion of TRP into L-5-hydroxytrypto-
phan (5-HTP) by tryptophan hydroxylase (TPH) [1]. As TPH is
not saturated at physiological concentrations of TRP, diminished
substrate availability for TPH decreases brain 5-HT synthesis and
release [1]. Therefore, serotonergic function can be temporarily
suppressed by using ATD, a method that is widely used in
psychiatric and pharmacological research [2,3]. Ingestion of a
TRP-free amino acid mixture provides a dose of large neutral
amino acids which compete with endogenous TRP for transport
across the blood-brain barrier, and subsequently lowers brain TRP
levels, 5-HT synthesis and levels of 5-HIAA, the primary
metabolite of 5-HT [4,5,6].
ATD has been used widely to probe serotonergic function in
humans. It can induce relapses in patients in remission from major
depression and other psychiatric disorders [3]. It can also lower
mood in healthy patients with a family history of depression [7].
Some authors even suggest using ATD as a predictive test for
personalized antidepressant treatment [8]. The limiting side effect
of ATD in human studies is the marked nausea that the amino
acid mixture can cause. A modified mixture, ATD Moja-De,
involves a body weight adapted administration of amino acids and
lower concentration of methionine relative to conventional
mixtures, which makes it less nauseating in humans. Its use has
proven to be a safe and effective method of TRP depletion even in
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children and adolescents [9,10,11,12,13,14,15]. It has been shown
that ATD Moja-De significantly lowers influx of TRP into the
brain in humans [16], but its specific effect on brain 5-HT has not
yet been established, which was the aim of this study. Another goal
of this study was to adapt ATD to mice in order to conduct
mechanistic studies of this widely used physiological manipulation.
There is a current debate about the efficacy and specificity of
ATD as regards the central nervous 5-HT system. ATD with
complex amino acid mixtures has been widely shown to decrease
5-HT synthesis and release in rat models [4,17,18,19]. However,
Van Donkelaar et al. [20] state that a TRP balanced control
condition (TRP+) has not yet been investigated thoroughly enough
to state it is a valid control condition in behavioral studies [20]. In
contrast, Crockett et al. [21] argue that the specificity of ATD
effects is clearly established [20]. Clinical data show that only
vulnerable human subjects show a change in behavior after ATD,
which may point to an individual vulnerability [20].
The purpose of the present study was to verify in an animal
model that ATD Moja-De, a revised mixture containing a
restricted set of amino acids (phenylalanine, leucine, isoleucine,
methionine, valine, threonine and lysine) significantly decreases
brain TRP and lowers 5-HT synthesis and release and to test the
possibility that individuals or populations with vulnerable 5-HT
systems are more sensitive to ATD. Numerous animal studies have
documented that ATD can be effective in rats [4,22] but none
have documented the efficacy of this treatment in mice. We used
mice in the present study in order to validate this model for future
studies in genetically manipulated animals. Only one study has
reported the effects of ATD in mice [23], but this study did not
verify inhibition of 5-HT synthesis. We evaluated 5-HT synthesis
by measuring the accumulation of the precursor 5-HTP after
decarboxylase inhibition with NSD 1015, and also quantitated 5-
HT and 5-HIAA content, as an indirect measure of 5-HT release
[24,25].
To test the effects of ATD Moja-De we used two strains of mice
that were predicted to respond differently to ATD based on
previously reported behavioral and neurochemical differences.
C57BL/6J (C57) mice have been reported to be resistant to the
effects of ATD [23] while BALB/cJ mice (BALBc) have a
mutation in TPH2 which lowers their baseline 5-HT production
[26,27] and would be predicted to exhibit an exaggerated response
to ATD. We hypothesized that ATD Moja-De would significantly
lower brain 5-HT synthesis and serotonergic activity, without
affecting dopamine or norepinephrine [28] and that BALBc mice
would exhibit a larger neurochemical response to ATD than C57
mice.
Materials and Methods
ATD Moja-De
The quantities of the Moja-De amino acid mixture lacking TRP
(TRP2) were as follows: L-phenylalanine 1.32 g, L-leucine 1.32 g,
L-isoleucine 0.84 g, L-methionine 0.5 g, L-valine 0.96 g, L-
threonine 0.6 g, L-lysine 0.96 g (quantities refer to a dose in
humans per 10 kg body weight). For the control balanced amino
acid mixture (TRP+), 0.7 g of L-TRP (per 10 kg body weight
corresponding to an administration in humans) were added to the
mix. The mixture was suspended in deionized water at a
concentration of 0.2 g/mL using a polytron and sonication bath.
Mice were treated with 2 g/kg BW delivered by oral gavage in two
doses of 10 mL/kg BW spaced 30 minutes apart. All amino acid
mixtures were prepared by the Pharmacy of University Hospital of
RWTH Aachen, Germany.
Animals
Male BALB/cJ mice and male C57BL/6J mice from Jackson
Laboratory (Bar Harbor, Maine, USA) were used. They were
given one week to acclimate to Duke University’s AALAC -
accredited vivarium before the study was initiated. The mice were
postnatal day (PD) 75 at the time of euthanasia. All procedures
were reviewed and approved by the Animal Care and Use
Committee at Duke University Medical Center. Mice were housed
in groups of 4 to 6 and maintained on a 12:12-h light-dark
schedule (lights on from 6.00 to 18.00 h), in a temperature-
controlled (2161uC) and air conditioned housing room. Food
(LabDiet, USA) and water were available ad libitum, except for the
nights before testing. Animal cages were provided with nestlets for
environmental enrichment. Clean cages were provided weekly.
Animals received two tests with the amino acid mixture separated
by two weeks. For the present study, they were food deprived
overnight, treated by gavage with TRP+, TRP2 or water followed
by saline or 3-hydroxybenzylhydrazine (NSD1015), and were
killed for determination of blood and brain TRP and neurotrans-
mitter levels.
Time Course
The time point of blood and brain collection was chosen based
on one previous study which reported on ATD in mice [23], and a
pilot time course in both strains of mice performed here to assess
the time course of maximal suppression of brain serotonergic
measures. Blood and brain samples were collected at the time of
gavage (0 minutes) or 90, 150, 210, 270 or 330 minutes after the
first gavage (n = 3–4/group for C57, n = 4–8/group for BALBc).
Blood and brains were processed as described below.
Behavior
The time course of the behavioral experiment is shown in
Table 1. Anxiety-like behavior was measured using the Light/
Dark-Test 2.5 hours after a treatment with the TRP+ mixture,
TRP2 or water. The test apparatus consisted of a clear Plexiglas
box lit at 450 lux and a dark Plexiglas insert. Both compartments
(40640620 cm) were connected by an 8.5 by 7.5 cm aperture.
Each mouse was placed in the dark compartment with the
aperture closed. The automatic recording was started as soon as
the door was lifted. Percent time spent in light, percent distance
traveled in light, latency to emerge into the light, entries into light,
total ambulations and pokes into light were automatically recorded
using an infrared beam frame and the Hamilton Kinder Motor
Monitor software.
Blood samples and brain tissue
The time course of the neurochemistry experiment is outlined in
Table 2 and was as follows: at t = 0, the first dose of TRP+, TRP2
or water was administered by gavage and repeated at t = 30 min.
Two hours after the first dose of amino acids or water, the animals
were injected i.p. with saline (1 ml/g BW) or the decarboxylase
inhibitor NSD-1015 (100 mg/kg BW in saline, 1 ml/g BW) to
inhibit TPH2. Measuring the accumulation of 5-HTP after
decarboxylase inhibition provides an estimate of TPH activity
[29]. Mice were anesthetized with isoflurane 150 min after the first
dose and blood was collected via cardiac puncture. Animals were
decapitated, brains collected and immediately dissected on ice.
Brains were sectioned in a brain block, and brain areas dissected
from 1 mm brain slices based on a mouse brain atlas. Prefrontal
cortex, frontal cortex and hippocampus were collected bilaterally,
immediately weighed and subsequently frozen on dry ice.
Prefrontal cortex was taken from slices of the most frontal part
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of the brain, which included only cortex and olfactory bulb. The
frontal cortex was set to be the cortex over the most frontal part of
the corpus callosum. Brain tissue was stored at 280uC until assay.
The average weight of PFC tissue in BALBc mice was
10.862.7 mg, in C57 mice it was 10.363.1 mg; the FC tissue
weighed 10.161.5 mg on average in BALBc mice and
11.162.2 mg on average in C57 mice; the hippocampus tissue
collected weighed 10.962.3 mg in BALBc mice and 10.562.0 mg
in C57 mice.
Biochemistry
Blood for assessment of TRP content was collected in
Eppendorf vials and kept on ice until centrifuged (16,0006g for
20 minutes at 4u Celsius) in order to separate the plasma. Plasma
samples were stored at 280uC. For brain TRP, 5-HTP, 5-HT, 5-
HIAA, norepinephrine (NE) and dopamine (DA) determination,
250 ml of an ice-cold buffer (0.5 mM sodium metabisulfate, 0.2N
perchloric acid and 0.5 mM EDTA) was added to the tissue. The
tissue was then homogenized by sonication. After a 10 minute spin
(16,0006g at 4uC) the supernatant was kept on ice until analysis.
The aliquot was used for two separate analyses of 5-HTP,
monoamines and their metabolites and for TRP-levels.
Brain neurotransmitter and metabolite content and 5 HTP
levels were quantified using a reverse phase high-performance
liquid chromatography (RP-HPLC) system with electrochemical
detection. The mobile phase for tissue content determination
contained 0.1 M sodium phosphate, 0.8 mM octanesulphonic
acid, 0.1 mM Na2EDTA and 18% methanol; the pH was adjusted
to 3.10 using hydrochloric acid and the flow rate was 0.7 ml/min.
Samples were quantified with a BAS Epsilon Electrochemical
Detector with dual 3 mm glassy carbon electrode (MF-1000) set to
0.70V.
A separate RP-HPLC system was used to measure TRP. The
mobile phase included 0.05 M citric acid, 0.05 M sodium
phosphate, 0.1 mM Na2EDTA and 8% acetonitrile; the pH was
not adjusted, and the flow rate was 1 ml/min. Samples were
quantitated with a BAS LC-4B detector set to 0.85V.
An external standard curve of all compounds was run on each
analysis day. The concentrations for total plasma TRP were
expressed in mg/ml plasma. The amount of brain TRP was
expressed as mg/mg tissue. The amount of 5-HT, DA and their
precursors and metabolites were expressed as ng/mg tissue.
Statistics
Mean and SEM concentrations were calculated for each
treatment group separately. Each dependent measure was
analyzed for all groups (water, TRP2, TRP+) using a global 4-
way ANOVA repeated measures analysis of variance (ANOVA)
with between factors strain, treatment and NSD and region as a
within factor (Table S1). Lower level ANOVAs were then
conducted to compare the TRP2 group to the TRP+ group to
the optimal test of the effects of ATD. Data from animals treated
with water alone were also analyzed using a repeated measures
ANOVA with the same factors but disregarding the treatment as a
between factor to identify strain differences in the baseline values
and response to NSD1015. Additional details about lower level
ANOVAs are provided in supplementary online materials
(Materials S1).
A post-hoc Fisher least protected significant difference test
(pLSD) was used to identify differences between specific treatment
groups. Outliers in biochemical data were identified by means of
GRUBBS. In all cases the level of statistical significance was set at
p,0.05. Analyses were performed using the Number Cruncher
Statistical System (NCSS) for Windows. Graphs were drawn using
Graph Pad Prism, version 5 for Windows (GraphPad Software,
San Diego, California, USA).
Results
Time Course
Data for plasma and hippocampus are shown in Figure 1. Data
for other brain areas were comparable. Dotted lines indicate times
at which TRP2 was administered. Two-way ANOVA of plasma
TRP yielded a significant effect of time (F (5,40) = 3.44, p,.012).
Post-hoc tests showed that time 0 was different from all other
times. For hippocampal TRP, ANOVA indicated a significant
Table 1. Time Course of Behavioral Experiment.
Time (min)
Overnight (4.30 p.m. until 9 a.m.) Food deprivation with water ad libitum
t = 0 First dose of TRP2, TRP+ (2 g/kg) or water (10 ml/kg BW)
t = 30 Second dose of TRP2, TRP+ (2 g/kg) or water (10 ml/kg BW)
t = 150 Testing in Light/Dark-Box
doi:10.1371/journal.pone.0035916.t001
Table 2. Time Course of Biochemistry Experiment.
Time (min)
Overnight (4.30 p.m. until 9 a.m.) Food deprivation with water ad libitum
t = 0 First dose of TRP+, TRP2 or water (10 ml/kg BW)
t = 30 Second dose of TRP+, TRP2 or water(10 ml/kg BW)
t = 120 Injection with NSD1015 or vehicle
t = 150 Blood draw via cardiac stick, then decapitation
doi:10.1371/journal.pone.0035916.t002
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effect of both strain (F (5,34) = 8.41, p,.006) and time (F
(5,34) = 23.81, p,.000001). Post-hoc tests showed that under
depletion hippocampal TRP in BALBc mice was slightly higher
than in C57 mice especially at later time points, although plasma
TRP was the same for both strains. Time 0 was different from all
other times. Finally, for 5-HIAA, ANOVA yielded a significant
effect of strain (F (5,40) = 11.96, p,.0014) and time (F
(5,40) = 6.54, p,.0002). Post-hoc tests showed that 5-HIAA was
lower in BALBc than in C57 mice and that time 0 was different
from time 90, 150 and 210. 5-HIAA was decreased more
consistently in C57 mice than in BALBc mice. This study showed
that plasma and hippocampal TRP remained suppressed for the
entire time course, but that 5-HIAA was decreased only at the
later times. Subsequent behavioral and biochemical studies were
conducted at 150 minutes, when effects on brain serotonergic
function were expected to be maximal.
Tryptophan
The effect of the amino acid mixtures on TRP relative to each
other and water are shown in Figure 2 (a, b, c) (the data have been
collapsed for NSD 1015 treatment since no effect was either
observed or expected). All data from both vehicle and NSD-
treated animals and details of the statistical results (lower level
ANOVAs, interactions, p and F values) are available as
supplementary online materials. TRP+ increased TRP relative
to water in all brain regions and strains, and TRP2 lowered TRP
comparably in all brain regions and strains relative to water (main
effect of treatment by ANOVA). Post-hoc tests showed that TRP
content of prefrontal cortex was lower than frontal cortex and
hippocampus. Overall, the results show that TRP+ and TRP2
amino acid mixtures effectively raised and lowered TRP in the
brain respectively, although the depletion condition was more
consistently effective than the control condition. The effects of the
TRP manipulations were similar in both the BALBc and C57
strains.
5-HTP
The effects of amino acid mixtures on 5-HTP relative to each
other and water after the administration of NSD 1015 are shown
in Figure 3 (a, b, c). This figure shows only values after NSD 1015,
as basal 5-HTP was at the limit of detection, as was expected. All
values from both saline and NSD-treated animals are available as
supplementary online material (Table S2). The ANOVA showed
main effects of strain, treatment, and region and interactions of
strain, treatment and region. TRP2 treatment differed from both
TRP+ and water, BALBc mice differed from C57 mice and
hippocampus varied from other regions. Lower level ANOVAs
and post-hoc analyses showed that: (1) TRP2 decreases 5-HT
synthesis in all assessed brain regions of C57 mice but not BALBc
mice as revealed by a treatment by strain interaction, (2) TRP+ did
not increase 5-HT synthesis as shown by a lack of an effect of
treatment on synthesis, and (3) at baseline, BALBc mice have a
lower level of 5-HT synthesis in the hippocampus and the
prefrontal cortex, but not in the frontal cortex as shown by a strain
by region interaction.
5-HT
The effects of the amino acid mixtures on 5-HT relative to each
other and water in vehicle-treated animals are shown in Figure 4
(a,b,c). All values from both saline and NSD-treated animals are
available as supplementary online materials. In summary, the 5-
HT findings show that (1) ANOVA showed main effects of strain,
treatment (TRP2 different from TRP+ and water) and region as
well as interactions of strain by region. Post-hoc tests showed that
(1) 5-HT content was lower at baseline in BALBc relative to C57
mice in the hippocampus, (2) TRP2 significantly decreased 5-HT
content relative to TRP+ in the hippocampus, but (3) TRP+ did
not consistently increase 5-HT content.
5-HIAA
The effect of the amino acid mixtures on 5-HIAA relative to
water and each other in vehicle-treated animals are shown in
Figure 5 (a, b, c). To summarize these overall findings it can be said
that (1) ANOVA showed significant effects of strain, treatment,
region and interactions of strain by region, treatment by region,
and their three-way interaction (strain by treatment by region). (2)
5-HIAA was decreased by TRP2 relative to TRP+ in every brain
region investigated and (3) 5-HIAA levels at baseline in BALBc
mice were lower than C57 mice in hippocampus and frontal
cortex, but not in the prefrontal cortex.
Other monoamines
DA, DOPAC and HVA did not show any strain differences
(p = .36, p= .53 and p= .50 respectively, data not shown) or effects
of treatment. Norepinephrine was not affected by any treatment
but was significantly lower in BALBc than C57 mice, which held
true for all treatment groups (water: F (1,20) = 27.09, p,.00005).
All values are available as supplementary online material.
Figure 1. Time course of ATD Moja-De in both strains. (a) Plasma=plasma tryptophan (mg/ml plasma) (b) HPC TRP= tryptophan in
hippocampus (mg/mg tissue) (c) HPC-5-HIAA=5-HIAA in hippocampus (ng/mg tissue). N = 3–4/group for C57, N = 4–8/group for BALBc. * different
from Time 0 and¤ different from corresponding group in BALBc mice.
doi:10.1371/journal.pone.0035916.g001
Acute Tryptophan Depletion in Mice
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e35916
Behavior
The effects of ATD on anxiety-like behavior (time in light) are
shown in Figure 6. Time in light and percent time in light yielded
similar results. None of the other parameters were different and
are not shown. Two-way ANOVA showed that the strains
responded differently to TRP2 (F (1,52) = 15.25, p,.0003 for
strain by treatment interaction). BALBc mice spent significantly
less time in the light than C57 mice, but after TRP2 BALBc mice
increased the time spent in light while C57 mice were not affected.
These data suggest that TRP2 was anxiolytic in BALBc but not
C57 mice.
Discussion
The main finding of this study is that the treatment with ATD
Moja-De (TRP2) decreased brain TRP and subsequently brain 5-
HT synthesis as shown by 5-HTP after decarboxylase inhibition
and by decreases in 5-HT and 5-HIAA levels of both strains of
mice relative to TRP+. The treatment was most effective in the
hippocampus, but also decreased serotonergic function in frontal
and prefrontal cortex. TRP2 decreased serotonergic function
more in C57 than in BALBc mice, in contrast to our prediction.
ATD did not affect dopamine, its metabolites or norepinephrine in
either of the two strains.
Although the ability of ATD to decrease 5-HT synthesis and
content is well established in rats and in humans [1,2,8], one
report in mice yielded equivocal results [23]. This may be due to
the differences in amino acid mixtures, since the other study used a
TRP-free protein-carbohydrate nutritional mixture. This mixture
contained more amino acids than Moja-De, which reduces the
fraction of TRP in the control mixture. That mixture was also not
administered based on body weight. The present results show that
5-HT synthesis was decreased, and that 5-HIAA levels decreased
more than 5-HT levels. These data suggest that 5-HT release was
reduced by this treatment. Although it has been proposed that
ATD might influence MAO activity [23], such an effect would not
explain the present results, as it would result in a concomitant
decrease in 5-HIAA and increase in 5-HT. Numerous (but not all)
rodent studies support the ability of ATD to decrease 5-HT
content [18,30]. The present results provide at least indirect
support for the latter finding that ATD transiently lowers
serotonergic function in the brain.
The effects of ATD were substantially greater in the
hippocampus than in cortical regions. There are several possible
explanations for this. First, it has been shown in mice and rats that
5-HT turnover varies by region [31,32]. This is likely due to
varying levels of afferent input for the specific raphe cell groups
that project to different areas as well as varying levels of
autoreceptor inhibition of cell firing. Studies with 5-HT1a agonists
and antagonists show that these effects are greatest in hippocam-
pus, which might explain the more rapid response to synthesis
inhibition [33,34].
Figure 2. Brain tryptophan. Brain tryptophan content in mg/mg tissue (a) prefrontal cortex (b) frontal cortex and (c) hippocampus. BALBc and C57
mice received two treatments by gavage of TRP+, TRP2 mixtures or water vehicle at 30 minute intervals followed by saline or NSD 1015 to inhibit
amion acid decarboxylase at 2 hours. Animals were killed 2.5 hours after the first treatment. Data are collapsed for NSD treatment as no significant
effects were predicted or observed. N= 11–12/group. * different from Water. +different from TRP+,¤ different from corresponding group in BALBc
mice. TRP+ and TRP2 effectively raised and lowered TRP respectively, although the depletion condition was more consistently effective than the
control condition. Similar effects were detected in both strains.
doi:10.1371/journal.pone.0035916.g002
Figure 3. Brain 5-HTP. Brain 5-HTP content in ng/mg tissue in (a) prefrontal cortex (b) frontal cortex and (c) hippocampus. Animals were treated as
described in Figure 2. Only NSD 1015-treated animals are shown. N = 6/group. * different from Water, +different from TRP+, ¤ different from
corresponding group in BALBc mice. TRP2 decreased 5-HT synthesis in all brain regions, but the results were only statistically relevant in C57 mice;
TRP+ did not increase 5-HT synthesis; at baseline, BALBc mice had a lower level of 5-HT synthesis in the hippocampus and the prefrontal cortex, but
not in the frontal cortex.
doi:10.1371/journal.pone.0035916.g003
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The deficient 5-HT synthesis in BALBc mice relative to other
strains was confirmed in this study. 5-HT synthesis and content
have been reported to be lower in BALBc mice than in strains
without a TPH2 mutation [26,27]. In the present study, 5-HT
synthesis was lower in BALBc than C57 mice, but 5-HT content
was lower only in hippocampus. This regional specificity has been
reported elsewhere [26], and may reflect strain-dependent
adaptations to the lower rate of 5-HT synthesis. In addition, the
affinity of this mutant form of the enzyme TPH2 has a higher
affinity for the substrate TRP [35], which could offset its lower
Vmax, especially under conditions of lower TRP availability.
Another possible explanation for the smaller strain difference in
the present study could be the food deprivation prior to testing or
differences in the time of day at sampling as TRP levels vary
significantly over the course of a day, mainly due to the timing of
meals [36].
The balanced amino acid mixture (TRP+) increased TRP
levels, but did not enhance 5-HT synthesis consistently. This was
unexpected, in particular because TPH2 is not saturated with
TRP under baseline conditions and due to animals having been
food deprived [37,38]. However, such studies have not been
conducted in mice. The TRP+ treatment did cause an increase of
5-HT content in BALBc mice, as predicted based on their lower
levels of 5-HT synthesis at baseline. The finding that TRP+ did
not consistently enhance 5-HT synthesis is of particular impor-
tance for human studies, as the latter employ the same amino acid
formulations as a control condition.
The depletion paradigm was more effective in C57 mice than in
BALBc mice, which contradicts our hypothesis. We predicted that
BALBc mice would be more affected by ATD since their 5-HT
synthesis is slowed by a TPH2 mutation [39]. There are several
possible explanations for this outcome. First, this study only looked
at one time point. However, the time course showed comparable
TRP depletion in both strains. More plausibly, the increased
affinity for TRP [35] exhibited by this mutation might render it
less sensitive to physiologic variation in TRP availability. BALBc
mice might also have developed a mechanism to compensate for
the lifelong decrease in TPH2 function. Alternatively, there might
be a threshold level below which 5-HT content cannot be
decreased with dietary manipulations. As BALBc mice are closer
to the threshold at baseline, they would reach this ‘‘floor effect’’
faster.
We found that BALBc mice have significantly lower norepi-
nephrine levels in all brain regions compared to C57 mice. This
could be a supplementary explanation for the anxious phenotype
of BALBc mice reported previously, especially since additional
impairment of 5-HT function by TRP depletion relieved rather
than exacerbated anxiety [40,41]. A slight (15%) difference in
norepinephrine content between these two strains has been
reported previously [42,43]. The larger difference reported here
may be due to starvation, but could also be an effect of strain
differences that have emerged since the studies were published.
Behavioral results showed strain selectivity in the effects of ATD
Moja-De on anxiety-like behavior. At baseline, BALBc are more
anxious then C57 mice, as one would expect based on previous
studies with this strain [44,45]. However, impairment of seroto-
nergic function has an anxiolytic effect on BALBc, but not on C57
mice, suggesting the BALBc mice have an increased vulnerability
towards a 5-HT imbalance while mice without a TPH2 mutation
can compensate for the impairment in synthesis. The directionality
Figure 4. Brain 5-HT. Brain 5-HT content in ng/mg tissue in (a) prefrontal cortex (b) frontal cortex and (c) hippocampus. Animals were treated as
described in Figure 2. Only vehicle treated animals are shown. N = 5–6/group. * different from Water, +different from TRP+, ¤ different from
corresponding group in BALBc mice. 5-HT content was lower at baseline in BALBc in the hippocampus; TRP2 significantly decreased 5-HT content in
the hippocampus; TRP+ did not consistently increase 5-HT content; TRP2 was consistently lower than TRP+ in all regions.
doi:10.1371/journal.pone.0035916.g004
Figure 5. Brain 5-HIAA. Brain 5-HIAA content in ng/mg tissue in (a) prefrontal cortex (b) frontal cortex and (c) hippocampus. Animals were treated
as described in Figure 2. Only vehicle treated animals are shown. N= 5–6/group. * different from Water, +different from TRP+, ¤ different from
corresponding group in BALBc mice. 5-HIAA was decreased by TRP2 in every brain region; a strain difference in 5-HIAA levels at baseline was seen in
hippocampus and frontal cortex, but not in the prefrontal cortex.
doi:10.1371/journal.pone.0035916.g005
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of the behavioral effects was unexpected, as we predicted 5-HT
depletion would have worsened anxiety-like behavior in BALBc
mice given their baseline 5-HT deficit. Adaptations to the lifelong
reduction in 5-HT synthesis might have contributed to the
observed responses after acute manipulations. Alternatively, the
behavioral results could reflect behavioral disinhibition in a
threatening situation, which is relieved by lowering serotonergic
function [46,47]. The latter scenario would predict greater effects
of ATD in the vulnerable (BALBc) genotype. Future experiments
will be necessary to resolve these two possibilities.
In summary, the major finding of this study was that ATD
Moja-De effectively impaired 5-HT synthesis and lowered 5-
HIAA content (an indirect measure of 5-HT release) in mice. The
establishment of this paradigm provides a model with which to
study the effects of mild serotonergic impairment in genetically
manipulated animals. Moreover, the present study suggested that
the TRP+ condition may not alter brain 5-HT synthesis, which
could make it a valid control condition for studies in humans. The
present results show that ATD Moja-De did not affect dopamine,
its metabolites or norepinephrine. The data of the present study
strongly support the conclusion that ATD Moja-De significantly
decreases central serotonergic function in mice and that this
decrease is specific for 5-HT relative to other monoaminergic
systems.
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